Cerulean Pharma, a clinical-stage biotech developing targeted cancer therapies for kidney and ovarian cancer, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol CERU. Cerulean initially filed confidentially on January 30, 2014. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.
